Metoprolol selectivity for beta-1 vs beta-2 receptors

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Metoprolol Beta-1 vs Beta-2 Receptor Selectivity

Beta-1 Selectivity of Metoprolol: Binding Affinity and Potency

Metoprolol is widely recognized as a beta-1 selective adrenergic receptor antagonist, meaning it preferentially blocks beta-1 receptors (primarily found in the heart) over beta-2 receptors (found in the lungs and other tissues) Golf1987Wahlund1990Abrahamsson1988. Studies using radioligand binding techniques in human and animal tissues consistently show that metoprolol has a much higher affinity for beta-1 receptors compared to beta-2 receptors. The selectivity ratio—how much more metoprolol prefers beta-1 over beta-2—has been reported to be about 30-40 fold in several studies Golf1987Wahlund1990Abrahamsson1988. This means metoprolol is about 30 to 40 times more likely to block beta-1 than beta-2 receptors at typical therapeutic concentrations.

Comparison with Other Beta-Blockers

When compared to other beta-blockers, metoprolol and atenolol have similar beta-1 selectivity, both being much more selective for beta-1 than beta-2 receptors, but less so than some newer agents like bisoprolol, which has even higher beta-1 selectivity Golf1987Abrahamsson1988Schliep1984. Non-selective beta-blockers like propranolol do not show this preference and block both receptor types equally William-Olsson2009Schliep1984.

Enantiomers and Stereoselectivity

Metoprolol exists as two enantiomers (S- and R- forms). The S-enantiomer is much more potent at beta-1 receptors than the R-enantiomer, with about 500 times greater affinity for beta-1 and about 50 times greater for beta-2. The racemic mixture (the form used clinically) maintains the overall beta-1 selectivity .

Functional and Clinical Implications

In functional studies, metoprolol’s beta-1 selectivity is evident in its effects on heart rate and contractility, with much less effect on beta-2 mediated processes such as bronchodilation or metabolic responses Minneman1979Jonkers1989William-Olsson2009. This selectivity is clinically important because it allows metoprolol to lower heart rate and blood pressure with less risk of causing bronchospasm or interfering with beta-2 mediated metabolic effects, which is especially relevant for patients with respiratory conditions like asthma.

Dose-Dependence of Selectivity

It is important to note that metoprolol’s beta-1 selectivity is dose-dependent. At low to moderate doses, it is highly beta-1 selective, but at higher doses, this selectivity diminishes and metoprolol can begin to block beta-2 receptors as well .

Conclusion

Metoprolol is a beta-1 selective adrenergic antagonist, showing about 30-40 times greater affinity for beta-1 than beta-2 receptors at therapeutic doses. This selectivity is consistent across different tissues and species, and is similar to atenolol but less than bisoprolol. The selectivity is most pronounced at lower doses and decreases at higher doses. This pharmacological profile underlies metoprolol’s clinical use for cardiovascular conditions with a lower risk of beta-2 mediated side effects.

Sources and full results

Most relevant research papers on this topic

Relative selectivity of different beta-adrenoceptor antagonists for human heart beta 1- and beta 2-receptor subtypes assayed by a radioligand binding technique.

Different beta-adrenoceptor antagonists show different relative selectivity for human heart beta 1- and beta 2-receptor subtypes, with atenolol and metoprolol showing similar potency and relative selectivity.

In Vitro Study

1987·

1citation

·S. Golf et al.

Scandinavian journal of clinical and laboratory investigation

The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol.

Metoprolol has a stricter steric requirement for binding to beta 1-adrenoceptors than beta 2-adrenoceptors, and both enantiomers exhibit a non-specific cardiodepressive effect at high doses.

In Vitro Study

1990·

4citations

·G. Wahlund et al.

British journal of pharmacology

Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes.

This study developed a method to determine the relative concentrations of -1 and -2-adrenergic receptors in tissues containing both receptor subtypes, revealing that there are two types of binding sites with different affinities in each tissue.

In Vitro StudyHighly Cited

1979·

403citations

·K. Minneman et al.

Molecular pharmacology·

DOI

The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung in vitro.

Beta-1 and beta-2 adrenergic receptors in rat heart and lung show distinct pharmacological specificities, with -1 receptors being more specific for activation and -2 receptors more specific for inhibition.

In Vitro StudyHighly Cited

1979·

243citations

·K. Minneman et al.

Molecular pharmacology·

DOI

A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers.

Metoprolol is a relatively beta-1 selective agent, while oxprenolol is more beta-2 selective, with pharmacokinetic-dynamic modeling being a suitable method for determining beta-2 selectivity.

1989·

17citations

·R. Jonkers et al.

The Journal of pharmacology and experimental therapeutics·

DOI

The beta 1- and beta 2-adrenoceptor affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea pig and man.

The beta 1- and beta 2-adrenoceptor affinities of atenolol and metoprolol remain unchanged in tissues from rats, guinea pigs, and humans, regardless of the radioligand used or tissue studied.

In Vitro Study

1988·

32citations

·T. Abrahamsson et al.

Biochemical pharmacology·

DOI

The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors.

Human heart beta-adrenergic receptors show heterogeneity, with approximately equal proportions of beta 1- and beta 2-adrenergic receptors in membranes.

In Vitro StudyHighly Cited

1983·

71citations

·P. Robberecht et al.

Molecular pharmacology·

DOI

Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration.

Propranolol and metoprolol both block beta-adrenergic stimulation, but metoprolol has a more selective beta1-blocking effect, while propranolol has a non-selective beta-blocking effect.

Non-RCTHighly Cited

2009·

98citations

·T. William-Olsson et al.

Acta medica Scandinavica·

DOI

Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

Bisoprolol, a new beta-adrenoceptor antagonist, demonstrates a pronounced beta 1-selectivity superior to that of known beta 1-selective antagonists in anesthetized dogs and guinea pigs.

Non-RCTAnimal Study

1984·

52citations

·H. Schliep et al.

Journal of cardiovascular pharmacology·

DOI

Race‐based therapeutics: A discussion surrounding heart failure trials

Metoprolol is a selective beta-1 receptor antagonist in low to moderate doses, but loses its selectivity at near maximum or maximum doses.

2007·

1citation

·D. Silber

Journal of the American Academy of Physician Assistants·

DOI

Try another search

levothyroxine 75 mcg dosage

spacetime foam models in quantum gravity

challenges of fly control in poultry farms

congestion relief methods

albuterol nebulizer pediatric dosing

robot navigation in unstructured environments